Tags

Type your tag names separated by a space and hit enter

Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany.
Int Clin Psychopharmacol. 2010 Jan; 25(1):29-36.IC

Abstract

The objective of this study was to evaluate long-term trends of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine prescriptions in Germany according to sex, age and type of prescribing medical specialist. We used data of the statutory health insurance company Gmünder ErsatzKasse for persons aged 65 years and older over the years 2000-2007. Trends in prescription prevalences were stratified and directly standardized. The standardized prescription prevalence of antidementia drugs in persons aged > or =65 years doubled in the period of 8 years in males (from 0.66% in 2000 to 1.32% in 2007) and in females (from 0.88 to 1.73%). We found significant 2.12-2.48-fold increases for the age group 80 years and above, smaller in the age group 70-79 years (1.57-1.94-fold) and no clear trend for those in the age range 65-69 years. The proportion of memantine prescribed by neurologists and psychiatrists increased from 22.6% in 2000 to 45.8% in 2007. Our study gives first insights into prescribing trends of antidementia drugs in Germany. Further evidence from health services research on dementia care is clearly needed.

Authors+Show Affiliations

University of Bremen, Centre for Social Policy Research, Division Health Economics, Health Policy and Outcomes Research, Ausser der Schleifmuehle 35-37, Bremen, Germany. hoffmann@zes.uni-bremen.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19934763

Citation

Hoffmann, Falk, et al. "Eight-year Prescription Trends of Memantine and Cholinesterase Inhibitors Among Persons 65 Years and Older in Germany." International Clinical Psychopharmacology, vol. 25, no. 1, 2010, pp. 29-36.
Hoffmann F, van den Bussche H, Glaeske G, et al. Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. Int Clin Psychopharmacol. 2010;25(1):29-36.
Hoffmann, F., van den Bussche, H., Glaeske, G., & Kaduszkiewicz, H. (2010). Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. International Clinical Psychopharmacology, 25(1), 29-36. https://doi.org/10.1097/YIC.0b013e3283339496
Hoffmann F, et al. Eight-year Prescription Trends of Memantine and Cholinesterase Inhibitors Among Persons 65 Years and Older in Germany. Int Clin Psychopharmacol. 2010;25(1):29-36. PubMed PMID: 19934763.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. AU - Hoffmann,Falk, AU - van den Bussche,Hendrik, AU - Glaeske,Gerd, AU - Kaduszkiewicz,Hanna, PY - 2009/11/26/entrez PY - 2009/11/26/pubmed PY - 2010/2/20/medline SP - 29 EP - 36 JF - International clinical psychopharmacology JO - Int Clin Psychopharmacol VL - 25 IS - 1 N2 - The objective of this study was to evaluate long-term trends of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine prescriptions in Germany according to sex, age and type of prescribing medical specialist. We used data of the statutory health insurance company Gmünder ErsatzKasse for persons aged 65 years and older over the years 2000-2007. Trends in prescription prevalences were stratified and directly standardized. The standardized prescription prevalence of antidementia drugs in persons aged > or =65 years doubled in the period of 8 years in males (from 0.66% in 2000 to 1.32% in 2007) and in females (from 0.88 to 1.73%). We found significant 2.12-2.48-fold increases for the age group 80 years and above, smaller in the age group 70-79 years (1.57-1.94-fold) and no clear trend for those in the age range 65-69 years. The proportion of memantine prescribed by neurologists and psychiatrists increased from 22.6% in 2000 to 45.8% in 2007. Our study gives first insights into prescribing trends of antidementia drugs in Germany. Further evidence from health services research on dementia care is clearly needed. SN - 1473-5857 UR - https://www.unboundmedicine.com/medline/citation/19934763/Eight_year_prescription_trends_of_memantine_and_cholinesterase_inhibitors_among_persons_65_years_and_older_in_Germany_ L2 - http://dx.doi.org/10.1097/YIC.0b013e3283339496 DB - PRIME DP - Unbound Medicine ER -